Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter

Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that didn't mean that the company had turned the corner with its struggling HCV franchise.

Gilead demonstrated that its HCV woes haven't gone away when the company announced its third-quarter results after the market closed on Thursday. The song remained pretty much the same as previous quarters this year. Here are the highlights.

Image source: Getty Images.

Source: Fool.com